Indivior PLC (LON:INDV – Get Free Report) fell 15.7% on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). 1,888,371 shares traded hands during trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group reissued a “buy” rating and set a GBX 1,800 ($22.74) target price on shares of Indivior in a research report on Tuesday, December 17th.
Check Out Our Latest Stock Analysis on Indivior
Indivior Stock Down 5.9 %
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
- Five stocks we like better than Indivior
- What is an Earnings Surprise?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- How to Invest in Insurance Companies: A Guide
- DuPont’s Electronics Spinoff: The Start of Something Big
- Stock Market Upgrades: What Are They?
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.